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Synthetic thiosemicarbazones and semicarbazones were evaluated for their Trypanosoma cruzi trypom-
astigotes obtained from LLC-MK2 cell cultures. In general, thiosemicarbazone derivatives were most
effective and among them the 4-N-(20-methoxy styryl)-thiosemicarbazone was chosen, to compare the
in vitro effect against amastigotes of T. cruzi lodged in mouse peritoneal and human macrophages. A
potent trypanocidal effect was observed that was more pronounced against parasites internalized in
human macrophages. A potential target for this compound was also evaluated by measuring the nitric
oxide synthase activity through NADPH consumption. A signiﬁcant decrease in enzyme activity was
observed. In contrast to the cytotoxic effect observed with benznidazole, no macrophage toxicity was
observed for any of the compounds, indicating that their activity was speciﬁc for the parasite forms
investigated.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Chagas’ disease is a leading cause of heart disease in the Amer-
icas. At least 8 million people are infected with Trypanosoma cruzi,
resulting in more than 14,000 deaths each year (DNDi, 2010). Mor-
bidity is relatively high, 17–30% of chronic chagasic patients dis-
play variable clinical manifestations, including cardiomyopathy
and pathological gastrointestinal dilation (Higuchi, 1995; Rezende,
1993). Chagas’ disease is generally transmitted to humans via
blood-sucking triatominea through an infectious metacyclic trypo-
mastigote form of this protozoan parasite (WHO, 2011). These
forms invade mammalian host cells where they change into the
intracellular amastigote form and replicate, primarily in muscle
cells, ﬁbroblasts and macrophages. Amastigotes then transform
back to trypomastigotes and, due to the rupture of the cells, the
infectious forms are released into the bloodstream, reaching other
cells and tissues and amplifying the infection (WHO, 2011). Treat-
ment options with nifurtimox (Lampit™) and benznidazole (Rada-
nil™, Rochagan™) for Chagas’ disease are limited due to their
limited effect towards different parasite isolates and disease
phases and systemic toxicity, which leads to adverse effects (Mayario de Bioquímica de Tripan-
idas Deane, sala 405, Rio de
9.
evier OA license.et al., 2007; Prata, 2001; Soeiro et al., 2009). Currently, most anti-
parasitic drugs are considered orphan drugs, with the main excep-
tion of antimalarials. The pharmaceutical considerations outweigh
all others, because the economic return on the development of
anti-parasitic drugs is limited. Therefore, it is necessary to ﬁnd less
expensive alternatives for the treatment of Chagas’ disease
(Cançado, 1997; Prata, 2001).
Thiosemicarbazones and semicarbazones are classes of com-
pounds with medical potential due to their capacity to inhibit
the growth of several pathogens (DoCampo, 1990). Those com-
pounds have been show to have antiviral, antibacterial, antitumor
and antimalarial activities (Dobek et al., 1980; Kalinowski et al.,
2007; Smee and Sidwell, 2003). Furthermore, studies concerning
their biological activity show that these compounds are active
against T. cruzi among others trypanosomatids (Beraldo and Gam-
bino, 2004; Fujii et al., 2005; Jeremy et al., 2008; Klayman et al.,
1979).
Some authors hypothesize that the structural speciﬁcity of
these compounds could have as targets intracellular components,
such as the enzyme ribonucleotide reductase, which is essential
for DNA synthesis and consequently for cellular division, or their
ability to these compounds to form complexes with metal cations,
allowing them to act as chelators (Bharti et al., 2003). The mecha-
nism of action of this class of molecule remains unclear, but it is
thought to occur through multiple targets, such as cysteine prote-
ases, present in various protozoa (Du et al., 2002; Greenbaum et al.,
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oxide) production, because of the crucial role that it plays as a cell
signaling agent and its function as an antileishmanial effector mol-
ecule (Genestra et al., 2003a,b,c, 2006; Paveto et al., 1995). Further-
more, more recent results from our laboratory also reported the
effect of drugs on the NO production by the Leishmania amazonen-
sis, corroboring the above data (Soares-Bezerra et al., 2008).
As part of our research into chemotherapy to treat diseases
caused by trypanosomatids, ﬁve thiosemicarbazones andTable 1
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high trypanocidal activity with low toxicity. In vitro experiments
using T. cruzi were carried out to evaluate the effect of these com-
pounds against cultured trypomastigotes (from LLC-MK2 cells) and
amastigotes lodged in both mouse and human macrophages. In
addition, the in vitro toxicity of those derivatives was evaluated
on murine macrophages. The enzymatic activity of the nitric oxide
synthase (NOS) of the parasite was also evaluated, because this en-
zyme could be a potential target for these compounds.ivatives (lM), toxicity to mice peritoneal macrophage (% cell death).
LD50/24 h lM % cell death Toxicity
NH2
1.6 0.1
NH2
0.4 0.1
NH2
1.8 0.1
NH2
1.4 0.1
NH2
1.5 0.1
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2.1. Chemistry
The semicarbazone/thiosemicarbazone derivativeswere synthe-
sized as described in the literature (Heilbron et al., 1923; Oliveira
et al., 2008). Benznidazole (Bz) (Rochagan – Roche) was obtained
from the Instituto de Pesquisa Evandro Chagas IOC/FIOCRUZ, Rio
de Janeiro, Brazil. All other reagents were obtained from Sigma
Chemical Co., St. Louis,MO, USA.Materials usedwere obtained from
commercial supplies and used without puriﬁcations, unless other-
wise noted. Melting points were determined with a Koﬂer (Jasco
DIP-370) apparatus, and they have not been corrected. Using tetra-
methylsilane as the internal reference, 1H and 13CNMR spectrawere
recorded on a Bruker AC-200 MHz instrument at room temperature.
The general procedure for preparation of thiosemicarbazones and
semicarbazones (1–5) was similar to that described in the literature
(Heilbron et al., 1923; Oliveira et al., 2008). Brieﬂy: amixture of cor-
responding aldehydes (2 mmol) and thiosemicarbazide or semi-
carbazide (2 mmol) was dissolved in ethanol (10 mL) with a few
drops of concentrated sulfuric acid for thiosemicarbazones or so-
dium acetate solution for semicarbazones. The resulting mixture
was stirred at room temperature for 1 h or until the reaction ﬁn-
ished, as observed by thin layer chromatography (TLC). The solvent
was removed under reduced pressure, and the resulting solid was
recrystallized from methanol to provide the thiosemicarbazones
1–3 and the semicarbazones 4–5. The compounds were fully char-
acterized as follows: 4-N-styryl-thiosemicarbazone (1): Yield 50%;
m.p. 94–96 C; 1H NMR (DMSO-d6) d: 11.40, 8.18, 7.89, 7.52, 7.40,
7.28 and 6.88; 13C NMR (DMSO-d6) d: 176.86, 144.26, 143.78,
138.11, 135.01, 128.07, 126.13 and 124.22. 4-N-(20-methoxy sty-
ryl)-thiosemicarbazone (2): Yield 82%; m.p. 186–188 C; 1H NMR
(DMSO-d6) d: 11.34, 8.14, 7.87, 7.57, 7.31, 7.17, 7.04, 6.98, 6.96
and 3.85; 13C NMR (DMSO-d6) d: 177.08, 156.38, 145.34, 133.48,
129.78, 126.96, 125.27, 123.66, 120.26, 111.07 and 55.04. 4-N-(40-
hydroxy-30-methoxybenzyl)-thiosemicarbazone (3): Yield 75%;
m.p. 204–206 C; 1H NMR (DMSO-d6) d: 9.34, 9.09, 8.46, 7.38,
7.23, 6.91 and 3.77; 13C NMR (DMSO-d6) d: 176.18, 147.22,
146.40, 132.70, 126.50, 123.46, 115.23, 111.02 and 55.54. 4-N-(20-
methoxy styryl)-semicarbazone (4): Yield 80%; m.p. 197 C; 1H
NMR (DMSO-d6) d: 10.15, 8.32, 7.40, 7.12, 7.07, 7.04, 6.99, 6.96,
3.85 and 2.98; 13C NMR (DMSO-d6) d: 156.17, 156.11, 142.23,
130.72, 129.30, 126.61, 125.85, 123.96, 120.25, 111.03 and 55.03.
4-N-(40-hydroxy-30-methoxybenzyl)-semicarbazone (5): Yield
76%; m.p. 216 C; 1H NMR (DMSO-d6) d: 10.28, 9.30, 7.27, 7.16,
7.12, 5.53, and 3.77; 13C NMR (DMSO-d6) d: 156.78, 147.88,
145.32, 137.19, 121.11, 119.0, 118.13, 112.17 and 55.85.2.2. Animals and parasites
Swiss mice (males, weighting 20–25 g) acquired from Centro de
Criação de Animais de Laboratório (CECAL)-FIOCRUZ were used to
obtain peritoneal macrophages for infection and isolation of T. cru-
zi. The experiments were conducted using a protocol approved by
the Comitê de Ética no Uso de Animais (CEUA-FIOCRUZ, protocol
number P0369-07). Trypomastigote forms of T. cruzi (Y strain)
were maintained by animal passage and used to infect the LLC-
MK2 cell lineage as previously described (Pinho et al., 2002). The
parasites obtained from this infection were used in all further
experiments.2.3. Drug assays
The compounds were tested (thiosemicarbazones 1–3 and the
semicarbazones 4 and 5) in a concentration range of 5–320lg/mL. The compounds were solubilized in dimethylsulfoxide
(DMSO) with the ﬁnal concentration of the solvent in the experi-
ments never exceeding 1.6%, which is not hazardous to the host
cells, then added to a 96 wells microplate and incubated at 37 C
for 24 h with T. cruzi trypomastigotes (obtained from LLC-MK2
cells, as described above) at a concentration of 4  106 cells/mL.
The drug effects were analyzed by counting the remaining para-
sites and/or based on the results from the 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) dye reduction
assay as described by Mosmann (1983). Brieﬂy, after the incuba-
tion time, 5 mg/mL MTT in PBS was added (22 lL/well) and the
plates were further incubated for 4 h at 37 C. The resulting forma-
zan crystals formed were dissolved with DMSO (80 lL/well) and
the samples were measured in a spectrophotometer at 490 nm.
Although all thiosemicarbazone and semicarbazone derivates were
used for the toxicity assays, only the most effective was used in the
following experiments. Tests were performed in triplicate and Bz
was used as a reference drug.
2.4. Cytotoxicity assay
The cytotoxic effect, expressed as the percentage of cell death,
was assayed using mouse peritoneal macrophages. The cells were
isolated from the peritoneal cavity of the animals in cold RPMI
1640 medium supplemented with 1 mM HEPES, Penicillin G
(105 IU/L) and streptomycin sulfate (10 g/L). Cells (2  105 per -
well) were cultivated at 37 C in a humidiﬁed 5% CO2 atmosphere.
After 2 h of incubation, the non-adherent cells were washed out
twice with RPMI. Test compounds and Bz were added in the high-
est concentration used in the activity test (320 lg/mL). Then, MTT
was applied to the wells as described above. Tests to quantify the
cytotoxicity on human macrophages were not performed due to
the limited number of cells available from each donor.
2.5. Nitric oxide synthase (NOS) activity
The NOS activity of T. cruzi trypomastigotes from cell cultures in
the absence (control) or presence of the most effective compound
was determined by measuring the NADPH consumption at 340 nm
because this cofactor is consumed during the conversion of L-argi-
nine to L-citrulline and nitric oxide (NO) by NOS (Genestra et al.,
2006). Brieﬂy, the complete enzyme reaction mixture contained
50 mM potassium phosphate buffer (pH 7.4), 1 mM CaCl2,
0.1 mM NADPH, 80 lM H4B, 10 lM FAD, 10 lM FMN, 0.1 mM L-
arginine, parasite extract (16.2 lg/mL of protein) and the com-
pound/Bz using a concentration corresponding to the in vitro
LD50/24 h in a ﬁnal volume of 1 mL. The control group contained
the components of the reaction mixture, except the drugs.
2.6. Growth inhibition of intracellular amastigotes
To evaluate the effect of the thiosemicarbazone 2, two cellular
preparations were used: (a) mouse macrophages were isolated
from the peritoneal cavity of Swiss mice using cold RPMI 1640
medium, supplemented with 1 mM HEPES, Penicillin G (105 IU/L)
and streptomycin sulfate (0.1 g/L); (b) human peripheral blood
mononuclear cells (PBMC) from eight health donors were sepa-
rated by Ficoll-Hypaque gradient centrifugation (Histopaque) from
Buffy coat preparation, and the monocyte-derived macrophages
were isolated by adherence. Brieﬂy, 2  106 cells (mouse/human
macrophages) were plated in Lab-Tek tissue chamber slides and
maintained in supplemented RPMI at 37 C, 5% CO2. One hour later,
the chambers were extensively washed with RPMI to remove non-
adherent cells, and the remaining adherent cells were subse-
quently cultured in RPMI medium containing 10% fetal calf serum
(FCS) during 24 h. After this time, the cultures were infected with
Fig. 1. Effect of (2-methoxy-styryl)-thiosemicarbazone on the infection of mouse
peritoneal macrophages by T. cruzi. Mouse peritoneal macrophages infected with
trypomastigote forms of T. cruzi (Y strain) and treated with (2-methoxy-styryl)-
thiosemicarbazone (102.5 ± 0 lg/mL). Sensitivities of intracellular amastigotes
were determined as MEM ± SD of triplicates of experimental groups. Control:
Infected macrophage without treatment or DMSO.
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the non-interiorized parasites were removed by washing the mac-
rophages three times with RPMI. The chosen compound was solu-
bilized in DMSO and added to the T. cruzi infected macrophage
cultures for 24 h, using a concentration corresponding to the
in vitro LD50/24 h. Drug activity was determined as the percentage
of the infected macrophages in drug-treated cultures compared to
the infected control (without treatment or DMSO), using optical
microscopy following methanol ﬁxation and Giemsa staining.
Quantiﬁcation of intracellular amastigotes was determined as the
MEM ± SD of three experiments (Alves et al., 2004; Bourguignon
et al., 2009). The protocol for the use of human cells was approved
by Comitê de Ética em Pesquisa (CEP/FIOCRUZ, No. 535/09).2.7. Light microscopy of the human macrophage experiment
The standard images of infection (without treatment) and the
morphology of human macrophages infected with T. cruzi and trea-
ted with 4-N-(20-methoxy styryl)-thiosemicarbazone (2), were
evaluated at 40 and 100 magniﬁcation using a digital system
DSC-W30 Sony camera ﬁtted with a zoom microscope-magnifying
lens, which produced enhanced black and white images yielding
image tiles of 6.0 megapixels, zoom 4.4 (Fig. 2).2.8. Statistical analysis
Data were analyzed using Student’s t test for signiﬁcance. P
values <0.05 were considered signiﬁcant.Table 2
Effect of (2-methoxy-styryl)-thiosemicarbazone on the infection of human macrophages by
and treated with (2-methoxy-styryl)-thiosemicarbazone (0.4 lM). Sensitivities of intracell
Infected macrophages without treatment or DMSO.
Human donors % of infected human macrophage ± SD
Control Thiosemicarbazone % of redu
1 48 ± 2.00 1.0 ± 1.70 97
2 66 ± 0.00 1,7 ± 1.50 96
3 38 ± 5.30 10.0 ± 2.50 72
4 48 ± 12.2 14.3 ± 0.60 70
5 10 ± 2.90 0.7 ± 0.60 94
6 11 ± 1.00 0.0 ± 0.00 100
7 27 ± 6.00 3.0 ± 1.00 73
8 08 ± 1.20 2.0 ± 1.00 793. Results and discussion
Current treatment for Chagas’ disease is primarily dependent on
benznidazole (Bz), a 2-nitroimidazole drug, which is the only drug
to treat Chagas’ disease available for human use in Brazil and
Argentina. This speciﬁc chemotherapy has limitations, such as a
lack of effectiveness to achieving parasitological cure or in the pre-
vention of the chronic phase of the disease, in addition to the emer-
gence of parasite resistance (Pérez-Rebolledo et al., 2008). There is
a considerable need for the development of new compounds to im-
prove the chemotherapy of Chagas’ disease.
Thiosemicarbazones and semicarbazones are an important class
of compounds that have been shown to have several biological
activities, including effects on pathogenic parasites. As a result,
they have been extensively studied in medicinal chemistry (Ber-
aldo and Gambino, 2004; Fabrino et al., 2004; Urbina, 1999). In
the present work, ﬁve derivatives of thiosemicarbazones and semi-
carbazones were evaluated in vitro against culture trypomastigotes
of T. cruzi. Among the compounds investigated, the compound 4-N-
(20-methoxy styryl)-thiosemicarbazone (2) was the most efﬁcient
with a LD50/24 h value of 0.4 lM, while Bz showed a lower activity
than the test compounds (1.8 lM). No macrophage toxicity was
observed by any of the compounds, indicating that their activity
was speciﬁc for the parasite forms investigated, while Bz presented
toxicity under our conditions. Evaluating the results of activity, it
appears that the addition of the methoxy group in the ortho posi-
tion of the aromatic ring and the presence of sulfur are associated
to an increase in the effectiveness of this thiosemicarbazone deri-
vate against this parasite form. Comparing the similarity of the
molecular structure of compounds 2 [4-N-(20-methoxy styryl)-thi-
osemicarbazone] and 4 [(4-N-(20-methoxy styryl)-semicarbazone],
it appears that the change of sulfur to oxygen signiﬁcantly reduced
the trypanocidal activity of compound 4, as the LD50 increased con-
siderably. The presence of hydroxyl and methoxy groups in meta
and para positions, respectively, and the absence of the styryl moi-
ety in compounds 3 and 5 do not improve the biological activity,
that is, they are not advantageous. In a comparative analysis of
data from our group, when thiosemicarbazones and semicarba-
zones were assayed against the blood stream forms of T. cruzi
and L. amazonensis promastigotes, a potent increase of the activity
was observed under speciﬁc conditions for each parasite form. In
addition, these compounds were more potent than pentamidine
and Bz, drugs used for the treatment of leishmaniasis and Chagas’
disease, respectively (Soares, 2007). Furthermore, a study compar-
ing the effectiveness of compound 2 in intracellular amastigotes
using mouse peritoneal and human macrophages was performed.
It is important to note that, in general, during the evaluation of
the in vitro drug activity, the protocols were always performed
using infected murine peritoneal macrophage because they are
very easy to obtain and manipulate. Our results indicate that this
thiosemicarbazone has a potent activity against intracellularT. cruzi. Human macrophages infected with trypomastigote forms of T. cruzi (Y strain)
ular amastigotes were determined as MEM ± SD of triplicates of each assay. Control:
No. of amastigote/human macrophage ± SD
ction Control Thiosemicarbazone % of reduction
3.5 ± 0.07 0.4 ± 0.75 88
3.8 ± 0.06 0.9 ± 0.81 76
5.7 ± 0.12 2.6 ± 0,32 55
2.4 ± 0.10 2.0 ± 0.10 17
1.5 ± 0.20 1.0 ± 1.00 23
1.5 ± 0.06 0.0 ± 0.00 100
1.5 ± 0.29 0.7 ± 0.25 59
2.0 ± 0.10 1.0 ± 0.00 50
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macrophages.
Assays using mouse macrophages infected with T. cruzi showed
that the treatment for 24 h with 0.4 lM of 4-N-(20-methoxy sty-
ryl)-thiosemicarbazone (2) resulted in a 54.5% reduction in the
mean percentage of infected macrophages and a 9.2% decrease of
intracellular parasites (Fig. 1).
The role of human macrophages is expected to vary since they
came for different individuals. Also, it is important to notice that
the differentiation of monocytes to macrophages that occurred
in vitro, would lead to changes in the cell behavior. These modiﬁca-
tions could be responsible for a potential variation in the infection
rate (de Souza et al., 2010) and in the parasite’s vulnerability with-
in the cell. In fact, even under the effect of all those different situ-
ations, the effectiveness of the compounds was much more evident
in assays conducted with infected human macrophages, with a
higher reduction in the percentage of the infected (70% in sample
number 4 to 100% in sample number 6). Infected macrophages of
donors 1, 2 and 5 showed excellent response to treatment, with
reductions of 97%, 96% and 94% in the number of infected host
cells, respectively (Table 2). Also, a strong reduction in the percent-
age of amastigote forms lodged in human macrophages was
observed in most of the studied samples. In this case, the percent-
age of trypanocidal activity of the compound against amastigote
forms was higher in human macrophages (samples 1, 2, 3, 6, 7
and 8), showing a decrease in the amount of parasites in a range
of 50–100%. However, samples 4 and 5 showed a considerableFig. 2. A light microscopy view of the effect of 4-N-(20-methoxy styryl)-thiosemicarbazo
Uninfected macrophages, (c, d) infected macrophages and (e, f) infected and treated witdecrease in the number of infected macrophages (70% and 94%),
while the decrease of the number of parasites within macrophages
was not signiﬁcant, as expected (Table 2).
There is a diverse range of molecular mechanisms through
which parasites can invade the host cell that may correspond to
differences in the available receptors on the surface of each speciﬁc
cell type (Gros et al., 2006). Also, it has been show that some sur-
face molecules in both mouse and human macrophages are pro-
teins that are structurally, functionally and antigenically different
(Saraiva et al., 2007). The differences observed in our experiments
comparing mouse and human macrophages could be related to
these observations. Our results show that this thiosemicarbazone
derivate was more potent against parasites within human cells,
which in some way mimic the in vivo situation more accurately
than mouse peritoneal macrophages. The evaluation of the effect
of 4-N-(20-methoxy styryl)-thiosemicarbazone (2) against amastig-
otes of T. cruzi lodged in human macrophages using light micros-
copy showed a complete elimination of the parasites, without
any hazardous effect to the macrophage of donor 1 (Fig. 2).
Data from literature demonstrated that trypanosomatids are
able to produce nitric oxide, through a constitutive nitric oxide
synthase (cNOS) that allows the parasites to survive within macro-
phages, participating in the host–parasite interaction (Basu et al.,
1997; Géigel and Leon, 2003; Genestra et al., 2003a,b; Paveto
et al., 1995; Pereira et al., 1997). In a search for a potential target
for compound 2, an assay was carried out to evaluate the effect
of this compound on the T. cruzi-NOS activity. The NOS activityne (2) against amastigotes of T. cruzi lodge in human macrophages (donor 1). (a, b)
h compound 2. Magniﬁcation 40 (a, c and e) and 100 (b, d and f).
Fig. 3. Evaluation of the activity of NOS from T. cruzi trypomastigotes, according to
the consumption of NADPH, in absence (control)/presence of 4-N-(20-methoxy
styryl)-thiosemicarbazone (2) and Bz. Data represent MEM ± SD of three indepen-
dent determinations.
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in the absence and presence of compound 2 and Bz. The results
showed that this compound and Bz were able to inhibit the en-
zyme activity approximately 6.5- and 2-fold, respectively, as dem-
onstrated by the decrease in NADPH consumption (Fig. 3).
These preliminary data allow us to suggest that the killing of T.
cruzi, as both intracellular amastigotes and culture cell trypom-
astigotes, would be associated to reduction of the parasite NOS
activity and not to the NO produced by the macrophages, which
means that this radical can not be considered a killer molecule. It
has been considered by several authors (Chen and Rosazza, 1994;
Fabrino et al., 2004; Paveto et al., 1995) that the parasite NOS activ-
ity and its capacity to produce NO, is a defense mechanism of try-
panosomatids. In this study, it was demonstrated that parasites
loose that capacity in the presence of the tested compound, and
as a probable consequence, became more sensitive to the toxic
molecules produced by macrophages.
In conclusion, this class of molecules presents high stability in
different conditions (Beraldo, 2004), and no signiﬁcant toxicity to
the host cells, encouraging us to continue the present investiga-
tions through both in vitro and in vivo experiments. Also, it is
important to carry out further studies of the metabolic pathways
occurring within this parasite, in order to deﬁne more precisely
the potential target for these compounds, as suggested by us.Acknowledgments
This investigation received ﬁnancial support from Fundação
Oswaldo Cruz (FIOCRUZ), Programa de Desenvolvimento Tecnológ-
ico em Insumos para Saúde (PDTIS), Conselho Nacional de
Desenvolvimento Cientíﬁco e Tecnológico (CNPq), Fundação de
Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), and
Departamento de Ciência e Tecnologia (DECIT).References
Alves, L.V., Cysne-Finkelstein, L., Temporal, R.M., Genestra, M.S., Leon, L., 2004. An
effective diaryl derivative against Leishmania amazonensis and its inﬂuence on
the parasite macrophage interaction. Journal of Enzyme Inhibition and
Medicinal Chemistry 19, 437–439.
Basu, N.K., Kole, L., Ghosh, A., Das, P.K., 1997. Isolation of a nitric oxide synthase
from the protozoan parasite, Leishmania donovani. FEMS Microbiology Letters
156 (1), 43–47.
Beraldo, H., 2004. Semicarbazonas e tiossemicarbazonas: o amplo perﬁl
farmacológico e usos clínicos. Química Nova 27, 461–469.
Beraldo, H., Gambino, D., 2004. The wide pharmacological versatility of
semicarbazones, thiosemicarba-zones and their metal complexes. Mini-
Reviews in Medicinal Chemistry 4, 31–39.Bharti, N., Shailendra, Sharma, S., Naqvi, F., Azam, A., 2003. New palladium(II)
complexes of 5-nitrothiophene-2-carboxaldehyde thiosemicarbazones.
Synthesis, spectral studies and in vitro anti-amoebic activity. Bioorganical
Medicinal Chemistry 3, 2923–2929.
Bourguignon, S.C. et al., 2009. Trypanosoma cruzi: in vitro activity of Epoxy-alpha-
Lap, a derivative of alpha-lapachone, on trypomastigote and amastigote forms.
Experimental Parasitology 122, 91–96.
Cançado, J.R., 1997. Terapêutica especíﬁca. In: Dias, Coura (Eds.), Clínica e
terapêutica da doença de Chagas Uma abordagem prática para o clínico geral.
FIOCRUZ, Rio de Janeiro, Brazil, pp. 323–351.
Chen, Y., Rosazza, J.P.N., 1994. A bacterial nitric oxide synthase from a Nocardia
species. Biochemical and Biophysical Research Communications 203, 1251–
1258.
de Souza, W., de Carvalho, T.M., Barrias, E.S., 2010. Review on Trypanosoma cruzi:
host cell interaction. International Journal of Cell Biology 2010, 1–18 (Article ID
295394).
DNDi, 2010. Drug of Neglected Diseases. <http://www.dndi.org/diseases/
chagas.html>.
Dobek, A.S., Klayman, D.L., Dickson Jr., E.T., Scovill, J.P., Tramont, E.C., 1980.
Inhibition of clinically signiﬁcant bacterial organisms in vitro by
2-acetylpyridine thiosemicarbazones. Antimicrobial Agents and
Chemotherapy 18, 27–36.
DoCampo, R., 1990. Sensitivity of parasites to free radical damage by antiparasitic
drugs. Chemico-biological Interactions 73, 1–27.
Du, X., Guo, C., Hansell, E., Doyle, P.S., Caffrey, C.R., Holler, T.P., McKerrow, J.H.,
Cohen, F.E., 2002. Synthesis and structure–activity relationship study of potent
trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine
protease cruzain. Journal of Medicinal Chemistry 45, 2695–2707.
Fabrino, D.L., Leon, L.L., Parreira, G.G., Genestra, M., Almeida, P.E., Melo, R.C., 2004.
Peripheral blood monocytes show morphological pattern of activation and
decreased nitric oxide production during acute Chagas’ disease in rats. Nitric
Oxide 11, 166–174.
Fujii, N. et al., 2005. Discovery of potent thiosemicarbazone inhibitors of rhodesain
and cruzain. Bioorganic and Medicinal Chemistry Letters 3 (15), 121–123.
Géigel, L.F., Leon, L.L., 2003. Cyclic 30–50 guanosine monophosphate-dependent
activity in Leishmania amazonensis. Memórias do Instituto Oswaldo Cruz 98,
499–500.
Genestra, M., Cysne-Finkelstein, L., Leon, L.L., 2003a. Comparative analysis of nitric
oxide production by Leishmania sp.. Medical Microbiology and Immunology
192, 217–223.
Genestra, M., Cysne-Finkelstein, L., Guedes-Silva, D., Leon, L.L., 2003b. Effect of L-
arginine analogs and a calcium chelator on nitric oxide (NO) production by
Leishmania spp.. Journal of Enzyme Inhibition and Medicinal Chemistry 18 (5),
445–452.
Genestra, M., Cysne-Finkelstein, L., Guedes-Silva, D., Leon, L.L., 2003c. Effect of
amidine derivatives on nitric oxide production by Leishmania amazonensis
promastigotes and axenic amastigotes. Nitric Oxide 8, 1–6.
Genestra, M., Souza, W.J., Guedes-Silva, D., Machado, G.M., Cysne-Finkelstein, L.,
Bezerra, R.J., Monteiro, F., Leon, L.L., 2006. Nitric oxide biosynthesis by
Leishmania amazonensis promastigotes containing a high percentage of
metacyclic forms. Archives of Microbiology 185 (5), 348–354.
Greenbaum, D.C. et al., 2004. Synthesis and structure–activity relationships of
parasiticidal thiosemicarbazone cysteine protease inhibitors against
Plasmodium falciparum, Trypanosoma brucei and Trypanosoma cruzi. Journal of
Medicinal Chemistry 47, 3212–3219.
Gros, L. et al., 2006. Evaluation of azasterols as anti-parasitics. Journal of Medicinal
Chemistry 49, 6094–6103.
Heilbron, I.M., Hudson, H.E., Huish, D.M., 1923. Phototropy. The reversed
phototropy of cinnamaldehyde semicarbazone and its methoxy derivatives.
Journal of the Chemical Society: Transactions 123, 2273–2279.
Higuchi, M.L., 1995. Chagas’ disease. Importance of the parasite in the
pathogenesis of the cardiac chronic disease. Arquivos Brasileiros de
Cardiologia 64, 251–254.
Jeremy, P.M. et al., 2008. Discovery of trypanocidal thiosemicarbazone inhibitors of
rhodesain and TbcatB. Bioorganic and Medicinal Chemistry Letters 18 (9),
2883–2885.
Kalinowski, D.S. et al., 2007. Design, synthesis, and characterization of novel iron
chelators: structure–activity relationships of the 2-benzoylpyridine
thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent
antitumor agents. Journal of Medicinal Chemistry 50, 3716–3729.
Klayman, D.L., Bartosevich, J.F., Grifﬁn, T.S., Mason, C.J., Scovill, J.P., 1979.
2-Acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial
agents. Journal of Medicinal Chemistry 22, 855–862.
Maya, J.D. et al., 2007. Mode of action of natural and synthetic drugs against
Trypanosoma cruzi and their interaction with the mammalian host. Comparative
Biochemistry and Physiology Part A: Molecular and Integrative Physiology 146,
601–620.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. Journal of Immunological
Methods 65, 55–63.
Oliveira, R.B., Souza-Fagundes, E.M., Soares, R.P., Andrade, A.A., Kretti, A.U., Zani,
C.L., 2008. Synthesis and antimalarial activity of semicarbazone and
thiosemicarbazone derivatives. European Journal of Medicinal Chemistry 43,
1983–1988.
Paveto, C. et al., 1995. The nitric oxide transduction pathway in Trypanosoma cruzi.
The Journal of Biological Chemistry 270, 16576–16579.
R.O.A. Soares et al. / Experimental Parasitology 129 (2011) 381–387 387Pereira, C., Paveto, C., Espinosa, J., Alonso, G., Flawiá, M.M., Torres, H.N., 1997.
Control of Trypanosoma cruzi epimastigote motility through the nitric oxide
pathway. The Journal of Eukaryotic Microbiology 44, 155–156.
Pérez-Rebolledo, A. et al., 2008. 4-Nitroacetophenone-derived thiosemicarbazones
and their copper(II) complexes with signiﬁcant in vitro anti-trypanosomal
activity. European Journal of Medicinal Chemistry 43, 939–948.
Pinho, R.T., Vannier-Santos, M., Alves, C.R., Marino, A.P., Castello Branco, L.R.,
Lannes-Vieira, J., 2002. Effect of Trypanosoma cruzi released antigens binding to
non-infected cells on anti-parasite antibody recognition and expression of
extracellular matrix components. Acta Tropica 83, 103–115.
Prata, A., 2001. Clinical and epidemiological aspects of Chagas’ disease. The Lancet
Infectious Diseases 1, 92–100.
Rezende, J.M., 1993. Manifestações clínicas da doença de chagas. In: Dani, R., Castro,
L.P. (Eds.), Gastro. Clin.. Guanabara Koogan, Rio de Janeiro, pp. 1729–1755.
Saraiva, J. et al., 2007. In vitro and in vivo activity of lignan lactones derivatives
against Trypanosoma cruzi. Parasitology Research 100, 791–795.
Smee, D.F., Sidwell, R.W., 2003. A review of compounds exhibiting ant-
orthopoxvirus activity in animal models. Antiviral Research 57, 41–52.
Soares, R.O.A., 2007. Avaliação da atividade e toxicidade de derivados de
tiossemicarbazonas e semicarbazonas contra Trypanosoma cruzi e Leishmania(L.) amazonensis in vitro. Ph.D. Thesis, Instituto Oswaldo Cruz, Fundação
Oswaldo Cruz, Brazil.
Soares-Bezerra, R.J., da Silva, E.F., Echevarria, A., Gomes-da-Silva, L., Cysne-
Finkelstein, L., Monteiro, F.P., Leon, L.L., Genestra, M., 2008. Effect of
mesoionic 4-phenyl-5-(cinnamoyl)-1,3,4-thiadiazolium-2-phenylamine
chloride derivative salts on the activities of the nitric oxide synthase and
arginase of Leishmania amazonensis. Journal of Enzyme Inhibition and Medicinal
Chemistry 23 (3), 328–333.
Soeiro, M.N.C., Dantas, A.P., Daliry, A., Silva, C.F., Batista, D.G.J., de Souza, E.M.,
Oliveira, G.M., Salomão, K., Batista, M.M., Pacheco, M.G.O., Silva, P.B., Santa-Rita,
R.M., Menna-Barreto, R.F.S., Boykin, D.W., de Castro, S.L., 2009. Experimental
chemotherapy for Chagas disease: 15 years of research contributions from
in vivo and in vitro studies. Memórias do Instituto Oswaldo Cruz 104, 301–310.
Urbina, J.A., 1999. Chemotherapy of Chagas’ disease: the how and the why. Journal
of Molecular Medicine 77, 332–338.
WHO, 2011. Chagas disease (American trypanosomiasis). <http://www.who.int/
mediacentre/factsheets/fs340/en/index.html>.
